Intrinsic Medicine

Executive Summary

Intrinsic Medicine is a Seattle-based biotechnology company founded in 2018, focusing on developing novel microbiome-based therapeutics for chronic inflammatory and metabolic diseases. By modulating the human microbiome, the company aims to address complex conditions with high unmet medical need, such as inflammatory bowel disease, metabolic syndrome, and other immune-mediated disorders. The approach leverages the growing understanding of host-microbiome interactions to create targeted small molecule or biologic therapies that restore microbial balance and reduce inflammation. While the company is still in preclinical or early clinical stages, it has the potential to tap into a multi-billion-dollar market for microbiome therapeutics. The biotech's progress will depend on successful advancement of its lead candidates through preclinical studies and into human trials, as well as securing partnerships or funding to support development.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 Clinical Trial for Lead Candidate40% success
• Q2 2026Presentation of Preclinical Efficacy Data at Major Conference (e.g., Digestive Disease Week)70% success
• TBDAnnouncement of Strategic Partnership or Licensing Deal with Larger Pharma30% success